Human Reproduction Update, Vol.8, No.1 pp.

6067, 2002

Mechanisms of abnormal uterine bleeding

Mark Livingstone1 and Ian S.Fraser2,3
1

Department of Reproductive Endocrinology, King George V and Royal Prince Alfred Hospitals, Camperdown, NSW and
Department of Obstetrics and Gynaecology, University of Sydney, NSW 2006, Australia

2
3

To whom correspondence should be addressed. E-mail: helena@obsgyn.usyd.edu.au

Over the past 10 years there has been an upsurge of interest in the mechanisms underlying normal and disturbed
menstrual bleeding. These studies have particularly focused on the mechanisms underlying the common problems of
menorrhagia associated with ovulatory and anovulatory dysfunctional uterine bleeding (DUB) and of unpredictable
breakthrough bleeding during hormonal contraceptive use. A wide range of abnormalities of endometrial
morphology and function have been demonstrated, but it is still not clear how all the pieces of this complex jigsaw
puzzle t together. Ovulatory DUB is predominantly associated with decreased endometrial vasoconstriction and
vascular haemostatic plug formation, leading to defective control of the volume of blood which is lost during
menstruation. By contrast, breakthrough bleeding is associated with a wide range of molecular disturbances which
appear to result in unpredictable vessel breakdown through disturbed endometrial angiogenesis, increased vascular
fragility and loss of the integrity of the endothelial, epithelial and stromal supporting structures. Anovulatory DUB is
very poorly understood, but may be associated with disturbed angiogenesis, fragile vessels and defective haemostatic
processes. Little is known about the actual mechanisms of the common problem of abnormal bleeding associated with
specic genital tract pathologies such as uterine myomata.
Key words: endometrium/menorrhagia/menstrual bleeding/progestogens

TABLE OF CONTENTS
Introduction
The nature of abnormal uterine bleeding
Mechanism of abnormal menstruation
Mechanisms involved in abnormal uterine bleeding
Abnormalities of regularity and frequency
Conclusion
References

Introduction
The spectrum of abnormal uterine bleeding affects up to one-third
of women of child bearing age and is therefore one of the
commonest complaints seen by family doctors and gynaecologists. These disturbances lead to considerable social and physical
morbidity in all societies, and may also be a reection of serious
underlying pathology. Menorrhagia affects 1030% of menstruating women at any one time, and may occur at some time during
the perimenopause in up to 50% of women (Ballinger et al., 1987;
Prentice, 1999). Disturbance of the menstrual pattern is almost
universal with long-acting methods of hormonal contraception,
although the patterns usually improve with time and most women
tolerate the changes well (Odlind and Fraser, 1990). Nevertheless,
>50% of women who prematurely discontinue use of these

60

methods cite menstrual disturbance as the main reason for this

decision. A similar problem is found with peri- or postmenopausal
hormone replacement therapy (Nachtigall, 1990).
The need to have a regular menstruation has been culturally
seenerroneouslyas essential for women's health and episodes
of amenorrhoea are still usually perceived as pathological. Many
women have rejected modes of contraception that did not give a
regular bleed, despite the fact that in primitive human cultures
women had many fewer periods in a lifetime as a result of later
menarche, more pregnancies, longer episodes of breast feeding and
earlier menopause (Short, 1976; Thomas and Ellertson, 2000).

The nature of abnormal uterine bleeding

The perception of menstrual bleeding varies considerably
amongst individual women. Studies designed to quantify
menstrual loss have demonstrated considerable inaccuracy in
subjective assessment of volume and women's recall of menstrual
events has been shown to be unreliable (Rodriguez et al., 1976;
Snowden, 1977; Fraser et al., 1984). This unreliability relates just
as much to perception of regularity, frequency, duration and dates
of events as to perception of volume.
Of those women who present with a clinically signicant
complaint of menorrhagia, <50% will have the complaint
European Society of Human Reproduction and Embryology

objectively conrmed (Chimbira et al., 1980; Fraser et al., 1981).

However, what is normal for one woman can be abnormal for
another and change in pattern may be important. Most research
techniques require dedicated subjects to maintain daily diary
records and to collect all sanitary towels for quantication. These
studies have shown mean menstrual blood loss to be ~30 ml per
cycle in most societies, with loss >6080 ml per month being
associated with an increased tendency towards iron deciency and
anaemia (Hallberg et al., 1966; Cole et al., 1971). An upper limit
of 60 ml may be more appropriate clinically. However, the total
menstrual loss is very dilute blood, since half is transudate from
the endometrium (Fraser et al., 1985).
The duration of normal menstruation also varies greatly, with
an average of 5 days and the heaviest loss usually on the rst 2
days (Matsumoto et al., 1962; Rubin and Crosignani, 1990).
Duration of ow is considered abnormal when it lasts <2 days or
>7 days.
The regularity and frequency of the menstrual cycle throughout
life has been well characterized (Treloar et al., 1967; Vollman,
1977). Abnormal uterine bleeding may involve any disturbance of
regularity, frequency, duration or volume of menstrual ow, and
the causes may be physiological, pathological or pharmacological
(Fraser and Sungertekin, 2000). Sound clinical management
demands that the underlying cause is dened. An understanding
of pathophysiological mechanisms may also be valuable in
determining appropriate therapies. Two of the most important
symptoms are menorrhagia and the occurrence of irregular
breakthrough bleeding with hormonal contraception, and emphasis will be placed on what is known about these mechanisms.

Mechanism of norma
(regulaa.725 0 TeTD
(et)Tj
1.ant5sp1
4.ccurrence)Ti2804 Tm
(Mechan)n

Mechanisms of abnormal uterine bleeding

acting as a bridge between platelets and injured vascular
endothelium. It circulates in plasma as a complex with factor
VIII, which it protects from proteolytic degradation. Certain
variants of Von Willebrand's Disease may be associated with
severe menorrhagia, but it is not yet clear how often less severe
variants cause moderate menorrhagia.
Defects involving the coagulation cascade, such as in chronic
liver disease, certain coagulation factor deciencies and with
excessive dosages of anticoagulants or increased activity of the
brinolytic system, less commonly result in menorrhagia. In a
patient who presents with menorrhagia, a family history of a
bleeding disorder, easy bruising or an increase in bleeding
associated with trauma should alert the clinician to the possibility
of a non-gynaecological cause.
Hypothyroidism may classically cause menorrhagia, probably
as a consequence of anovulatory dysfunctional uterine bleeding
(DUB), but it is a rare cause of this symptom. Most women with
untreated hypothyroidism and hyperthyroidism will develop
amenorrhoea.
Dysfunctional uterine bleeding

DUB is a diagnosis of exclusion and a common cause of the

symptom, `menorrhagia'. These terms are frequently and
mistakenly used synonymously and there is a great deal of
confusion as to exactly which types of abnormal bleeding should
be termed DUB. All are agreed that the terms should refer to
excessive bleeding without pelvic pathology, but in the USA, the
denition of `dysfunctional uterine bleeding' refers predominantly to anovulatory bleeding and the term `menorrhagia' to both
the symptom of excessive bleeding and to the diagnosis of
ovulatory dysfunctional bleeding (Cowan, 1992; Fraser and
Sungurtekin, 2000). This is quite different from most of the rest
of the world. Our favoured denition of DUB, which has been
endorsed by the European Society for Human Reproduction and
Embryology, is `excessive bleeding (excessively heavy, prolonged or frequent) of uterine origin which is not due to
demonstrable pelvic disease, complications of pregnancy or
systemic disease' (Rubin and Crosignani, 1990; Fraser and
Sungurtekin, 2000). Dysfunctional uterine bleeding accounts for
~50% of all cases of excessive menstruation (Beazley, 1972) and
is ovulatory in ~80% of cases (Cameron, 1989; Fraser, 1989).
Anovulatory DUB. Anovulatory DUB is recognizable as irregular,
prolonged and usually excessive bleeding caused by a disturbed
function of the hypothalamicpituitaryovarian axis. It is most
commonly seen in polycystic ovary syndrome and at the extremes
of female reproductive life, namely the perimenarchal and
perimenopausal years. At these stages of life, cycles may be
intermittently ovulatory and anovulatory, thus leading to great
irregularity of menstruation as well as great variability in blood
loss.
The exact mechanisms behind anovulatory bleeding are
uncertain (Fraser et al., 1996) but it is known that unopposed
estrogen can lead to excessive endometrial proliferation and
hyperplasia with increased and dilated draining veins and
suppression of spiral arterioles (Beilby et al., 1971). Large,
thin-walled, tortuous, supercial endometrial vessels can often be
demonstrated on the surface of hyperplastic endometrium
(Hamou, 1985) and increased fragility is a probable contributor

to increased blood loss. Unopposed estrogen has a direct effect on

the uterine blood supply by reducing vascular tone (Fraser et al.,
1987) and possibly an indirect effect through inhibiting
vasopressin release (Akerlund et al., 1975) leading to vasodilatation and increased blood ow. Unopposed estrogen also
stimulates stromal VEGF expression which may contribute to
disturbed angiogenesis (Zhang et al., 1995; Smith, 1998). In
addition, endometrium exposed to prolonged, unopposed estrogen
synthesizes less PG and a higher proportion of PGE than PGF
(Smith et al., 1982).
In women with endometrial hyperplasia, the endometrium often
breaks down unevenly, even when circulating estrogen concentrations are high or rising (Brown et al., 1959), with scattered red
patches at hysteroscopy corresponding to thrombotic foci of
necrotic disintegration, adjacent to the abnormally proliferated
endometrium (Schroder, 1954). An increased production of
endometrial nitric oxide (endothelium-derived relaxing factor)
in response to excessive and unopposed estrogen has been
postulated as another mechanism leading to excessive blood loss
in anovulatory menstruation (Chwalisz and Gareld, 2000).
Ovulatory DUB. Ovulatory DUB is characterized by regular
episodes of heavy menstrual loss, with 90% of the loss on the
rst 3 days as in normal menstruation (Haynes et al., 1979). There
is no disturbance of the hypothalamicpituitaryovarian axis and
indeed the gonadotrophin and steroid hormone proles are no
different to those seen in a normal menstrual cycle (Haynes et al.,
1979; Eldred and Thomas, 1994).
The decline in estrogen and progesterone levels in the late
luteal phase initiates many processes which act simultaneously,
leading to disintegration then re-epithelialization of the functional
layer of the endometrium during menstruation. There is little
evidence to suggest that there are substantial abnormalities in the
sequence of processes of breakdown, regeneration or remodelling
of the endometrium leading to the increased menstrual loss in
ovulatory DUB. The main defect appears to be in the control of
processes regulating the volume of blood lost during menstrual
breakdown of the endometrium, primarily the processes of
vasoconstriction and haemostasis.
Alterations of follicular phase endometrial blood ow have
been noted in women with ovulatory DUB and may reect or
inuence disturbances of function occurring in the tissue (Fraser
et al., 1987). Endometrial glandular and stromal estrogen and
progesterone receptor levels may be increased in the late secretory
phase in women suffering from DUB (Gleeson et al., 1993) and
these may be responsible for mediating the effects of increased
estrogen. However, others have not been able to demonstrate
differences in expression of these receptors in women with
menorrhagia (Critchley et al., 1994).
Endometrial small surface vessels were studied at hysteroscopy
in women with ovulatory DUB (Hickey et al., 1996), and these
vessels appear to be similar in size and appearance to those of
normal women (Hickey et al., 1996, 1998). These vessels also
appear to be normal in their response to intrauterine stretching, in
direct contrast to the increased fragility exhibited by small
endometrial vessels exposed to low dose progestogens, such as
Norplant (Hickey et al., 2000a). However, minor abnormalities of
endometrial and myometrial veins have been described (Hourihan
et al., 1989).

63

Mechanisms of abnormal uterine bleeding

acting as a bridge between platelets and injured vascular
endothelium. It circulates in plasma as a complex with factor
VIII, which it protects from proteolytic degradation. Certain
variants of Von Willebrand's Disease may be associated with
severe menorrhagia, but it is not yet clear how often less severe
variants cause moderate menorrhagia.
Defects involving the coagulation cascade, such as in chronic
liver disease, certain coagulation factor deciencies and with
excessive dosages of anticoagulants or increased activity of the
brinolytic system, less commonly result in menorrhagia. In a
patient who presents with menorrhagia, a family history of a
bleeding disorder, easy bruising or an increase in bleeding
associated with trauma should alert the clinician to the possibility
of a non-gynaecological cause.
Hypothyroidism may classically cause menorrhagia, probably
as a consequence of anovulatory dysfunctional uterine bleeding
(DUB), but it is a rare cause of this symptom. Most women with
untreated hypothyroidism and hyperthyroidism will develop
amenorrhoea.
Dysfunctional uterine bleeding

DUB is a diagnosis of exclusion and a common cause of the

symptom, `menorrhagia'. These terms are frequently and
mistakenly used synonymously and there is a great deal of
confusion as to exactly which types of abnormal bleeding should
be termed DUB. All are agreed that the terms should refer to
excessive bleeding without pelvic pathology, but in the USA, the
denition of `dysfunctional uterine bleeding' refers predominantly to anovulatory bleeding and the term `menorrhagia' to both
the symptom of excessive bleeding and to the diagnosis of
ovulatory dysfunctional bleeding (Cowan, 1992; Fraser and
Sungurtekin, 2000). This is quite different from most of the rest
of the world. Our favoured denition of DUB, which has been
endorsed by the European Society for Human Reproduction and
Embryology, is `excessive bleeding (excessively heavy, prolonged or frequent) of uterine origin which is not due to
demonstrable pelvic disease, complications of pregnancy or
systemic disease' (Rubin and Crosignani, 1990; Fraser and
Sungurtekin, 2000). Dysfunctional uterine bleeding accounts for
~50% of all cases of excessive menstruation (Beazley, 1972) and
is ovulatory in ~80% of cases (Cameron, 1989; Fraser, 1989).
Anovulatory DUB. Anovulatory DUB is recognizable as irregular,
prolonged and usually excessive bleeding caused by a disturbed
function of the hypothalamicpituitaryovarian axis. It is most
commonly seen in polycystic ovary syndrome and at the extremes
of female reproductive life, namely the perimenarchal and
perimenopausal years. At these stages of life, cycles may be
intermittently ovulatory and anovulatory, thus leading to great
irregularity of menstruation as well as great variability in blood
loss.
The exact mechanisms behind anovulatory bleeding are
uncertain (Fraser et al., 1996) but it is known that unopposed
estrogen can lead to excessive endometrial proliferation and
hyperplasia with increased and dilated draining veins and
suppression of spiral arterioles (Beilby et al., 1971). Large,
thin-walled, tortuous, supercial endometrial vessels can often be
demonstrated on the surface of hyperplastic endometrium
(Hamou, 1985) and increased fragility is a probable contributor

to increased blood loss. Unopposed estrogen has a direct effect on

the uterine blood supply by reducing vascular tone (Fraser et al.,
1987) and possibly an indirect effect through inhibiting
vasopressin release (Akerlund et al., 1975) leading to vasodilatation and increased blood ow. Unopposed estrogen also
stimulates stromal VEGF expression which may contribute to
disturbed angiogenesis (Zhang et al., 1995; Smith, 1998). In
addition, endometrium exposed to prolonged, unopposed estrogen
synthesizes less PG and a higher proportion of PGE than PGF
(Smith et al., 1982).
In women with endometrial hyperplasia, the endometrium often
breaks down unevenly, even when circulating estrogen concentrations are high or rising (Brown et al., 1959), with scattered red
patches at hysteroscopy corresponding to thrombotic foci of
necrotic disintegration, adjacent to the abnormally proliferated
endometrium (Schroder, 1954). An increased production of
endometrial nitric oxide (endothelium-derived relaxing factor)
in response to excessive and unopposed estrogen has been
postulated as another mechanism leading to excessive blood loss
in anovulatory menstruation (Chwalisz and Gareld, 2000).
Ovulatory DUB. Ovulatory DUB is characterized by regular
episodes of heavy menstrual loss, with 90% of the loss on the
rst 3 days as in normal menstruation (Haynes et al., 1979). There
is no disturbance of the hypothalamicpituitaryovarian axis and
indeed the gonadotrophin and steroid hormone proles are no
different to those seen in a normal menstrual cycle (Haynes et al.,
1979; Eldred and Thomas, 1994).
The decline in estrogen and progesterone levels in the late
luteal phase initiates many processes which act simultaneously,
leading to disintegration then re-epithelialization of the functional
layer of the endometrium during menstruation. There is little
evidence to suggest that there are substantial abnormalities in the
sequence of processes of breakdown, regeneration or remodelling
of the endometrium leading to the increased menstrual loss in
ovulatory DUB. The main defect appears to be in the control of
processes regulating the volume of blood lost during menstrual
breakdown of the endometrium, primarily the processes of
vasoconstriction and haemostasis.
Alterations of follicular phase endometrial blood ow have
been noted in women with ovulatory DUB and may reect or
inuence disturbances of function occurring in the tissue (Fraser
et al., 1987). Endometrial glandular and stromal estrogen and
progesterone receptor levels may be increased in the late secretory
phase in women suffering from DUB (Gleeson et al., 1993) and
these may be responsible for mediating the effects of increased
estrogen. However, others have not been able to demonstrate
differences in expression of these receptors in women with
menorrhagia (Critchley et al., 1994).
Endometrial small surface vessels were studied at hysteroscopy
in women with ovulatory DUB (Hickey et al., 1996), and these
vessels appear to be similar in size and appearance to those of
normal women (Hickey et al., 1996, 1998). These vessels also
appear to be normal in their response to intrauterine stretching, in
direct contrast to the increased fragility exhibited by small
endometrial vessels exposed to low dose progestogens, such as
Norplant (Hickey et al., 2000a). However, minor abnormalities of
endometrial and myometrial veins have been described (Hourihan
et al., 1989).

63

M.Livingstone and I.S.Fraser

A range of endometrial molecular systems have been studied in
preliminary fashion in women with ovulatory DUB and some
functional abnormalities have been demonstrated. Endothelins
probably act on receptors at the endometrialmyometrial interface, which increase at the time of normal menstruation (Cameron
et al., 1992). Reduced levels of endothelins may lead to an
increase in the volume of blood lost, and Marsh et al. have
demonstrated less intense endothelin-like immunoreactivity in
endometrial glandular and luminal epithelium in women with
menorrhagia than in controls (Marsh et al., 1996).
This may be one of the more important mechanisms limiting
blood loss in normal menstruation. PGs also have powerful
vasoactive effects and extensive evidence points to an important
role in the prevention of excessive menstrual blood loss (Baird et
al., 1996). Endometrial PG release is greatly inuenced by
circulating steroid levels (Smith and Kelly, 1987). PGF2a induces
vasoconstriction and PGE2 and prostacyclin (PGI2) induce
vasodilation. PGI2 is also one of the most potent substances
known for preventing platelet aggregation and the formation of
haemostatic plugs. An increase in total PG release and
disproportionate rise in PGE2 have been demonstrated in
ovulatory DUB (Smith et al., 1981a). It has also been shown
that there is an increase in PGE2 and PGI2 receptors, predisposing
to vasodilatation, in women with menorrhagia (Adelantado et al.,
1988). A potential for increased synthesis of PGI2 by myometrium from endometrial precursors in ovulatory DUB has also
been clearly demonstrated (Smith et al., 1981b).
Antiprostaglandin medications are effective in treating ovulatory
DUB, probably mainly by reducing endometrial synthesis of all
PGs, but also by inhibiting the binding of PGE to its receptors.
Haemostatic mechanisms are very important in limiting the
volume of blood lost at menstruation. Prevention of platelet
aggregation by increased PGI2 release may be an important
contributing factor in ovulatory DUB (Smith et al., 1981b) as may
increased endometrial tissue plasminogen activator content,
increased local brinolytic activity (Bonnar et al., 1983;
Casslen et al., 1986; Gleeson et al., 1993) and excessive
endometrial heparin-like activity (Paton et al., 1980). This
combination of increased PGI2, brinolysis and heparin-like
activity will result in very limited and decient haemostatic plug
formation. Mast cells degranulate at menstruation to release a
number of substances including heparin, which reduces brin
formation, and histamine which causes endothelial cell contraction, resulting in gaps between the vascular endothelial cells and
both transudation and red cell loss. In women with ovulatory
DUB or with menorrhagia secondary to the use of an IUCD, an
increase in the enzymatic activity of lysosomes has also been
demonstrated (Wang et al., 2000). This may contribute to
abnormalities of the process of tissue breakdown and remodelling.
Matrix metalloproteinases may be even more important in
contributing to abnormal endometrial breakdown and abnormalities of menstrual bleeding (Salamonsen et al., 2000).
When other systems are also investigated in detail, it is likely
that other disturbances of molecular function will be demonstrated. Recent research has begun to focus on the activation of
specic genes which may be associated with abnormal uterine
bleeding of various types. A novel gene called `endometrial
bleeding associated factor' (ebaf) has recently been demonstrated
to be transiently expressed in endometrium at normal menstrua-

64

tion, and much more strongly expressed when bleeding is

abnormal (Kothapalli et al., 2000). This gene is located on
chromosome 1 and codes for a member of the TGFb superfamily.
The exact function is not clear. The concept of multigene
activation patterns is now being explored as a possible
explanation for complex functional disturbances of the type
exemplied by ovulatory DUB.
Abnormalities of regularity and frequency
Oligomenorrhoea, amenorrhoea and polymenorrhoea

These disturbances of menstrual regularity are all associated with

disturbances of the hypothalamicpituitaryovarian axis and do
not fall directly within the remit of this review. Oligomenorrhoea
may sometimes be associated with anovulatory DUB, especially
during adolescence (Fraser et al., 1973).
Intermenstrual and postcoital bleeding, premenstrual spotting

These symptoms are usually superimposed on otherwise normal

and regular menstrual periods, and are mainly caused by surface
lesions of the genital tract (such as cervical or endometrial polyps,
infection or carcinoma) (Fraser and Petrucco, 1996). Actual
pathophysiological mechanisms leading to this abnormal bleeding
are poorly understood, but are probably due to the presence and
dilatation of abnormal surface vessels on these lesions.
Breakthrough bleeding

Breakthrough bleeding (BTB) is one of the commonest reasons

for women to discontinue hormonal contraceptive use, even
though most BTB is usually prominent mainly in the rst few
months of treatment. The oral contraceptive pill contains both
estrogen and progesterone and BTB is not a common reason for
discontinuation of use as >90% of pill users report no disturbance
of their bleeding patterns (Belsey et al., 1988). Most episodes of
BTB are caused by missed pills or the occasional failure of a
withdrawal bleed. Any other factor interfering with the circulating
concentrations of contraceptive steroids can lead to BTB and it is
especially common when simultaneous medications, such as
anticonvulsants, interact.
Progestogen-only contraceptives now come in many different
forms with a range of contraceptive effects at all levels of the
hypothalamicpituitaryovarian axis. Depot medroxyprogesterone acetate (DMPA) produces highly unpredictable bleeding
patterns with a substantial incidence of amenorrhoea, oligomenorrhoea and erratic, frequent and prolonged light bleeding and
spotting, while lower dose preparations like the subdermal
levonorgestrel implant system, Norplant, produce some unpredictable, irregular light bleeding which is somewhat better
tolerated. Nevertheless, all progestogen-only systems produce
unpredictable bleeding which many women eventually nd
intolerable (Belsey et al., 1988). With most methods the bleeding
pattern improves with time.
This unpredictable light bleeding and spotting is caused by
continuous exposure of the endometrium to relatively constant
doses of progestogen, with simultaneous exposure to low levels of
estrogen. This results in a variety of endometrial histological
pictures which are broadly described as `suppressed secretory' but
sometimes verge on complete atrophy (Maqueo, 1980). Surface

Mechanisms of abnormal uterine bleeding

breakdown of the endometrium is erratic and does not occur
synchronously over the whole surface (Hickey et al., 1996).
Hysteroscopic studies in Norplant users have shown irregular
surface breakdown which correlates positively with the duration
of BTB over the previous month (Hickey et al., 1996). These
same hysteroscopic studies have also demonstrated abnormal
angiogenesis with neovascularization patterns over the endometrial surface. These vessels vary considerably in size and some are
much wider in diameter and thinner-walled than normal (Hickey
et al., 1998). These vessels are also much more fragile than
normal and bleed easily in response to minor stress (Hickey et al.,
2000a). There are also disturbances in surface vessel ow and
capillary vasomotion as demonstrated by laser Doppler probe
(Hickey et al., 2000b). All of these abnormalities are a reection
of disturbed angiogenesis.
The cause of the increased vascular fragility is not entirely
clear (Fraser and Diczfalusy, 1980; Hickey et al., 1996), but there
is important evidence that endometrial pericytes (Rogers et al.,
2000) and basement membrane composition are decient in many
of these women (Hickey et al., 1999). There is limited evidence
that endothelial tight junctions and adhesion molecule expression
may also be affected. In order for bleeding to occur, the surface
epithelium must also be breached, and limited evidence indicates
that progestogen exposure leads to loosening of the surface
epithelial attachments (Murphy, 2000).
Increasing evidence points to a series of disturbances of cellular
and molecular function in the endometrium of women exposed to
continuous progestogens, all of which could contribute to
disturbed angiogenesis, increased spontaneous tissue breakdown
or defective repair (Hickey and Fraser, 2000). These include
increased expression of matrix metalloproteinases (Marbaix et al.,
2000; Salamonsen et al., 2000; Vincent and Salamonsen, 2000),
endothelial cell dysfunction (Rodriguez-Manzaneque et al.,
2000), vascular endothelial growth factor (Charnock-Jones et
al., 2000), reduced epithelial cytokeratin expression
(Wonodirekso et al., 2000), increased expression of tissue factor
(Lockwood et al., 2000), multiple alterations in concentrations
and functions of migratory endometrial leukocytes (Song et al.,
1995; Clark et al., 1996) and a range of other disturbed
angiogenic factors (Smith, 2000).
It should not be forgotten that many cases of BTB in modern
clinical practice are associated with the use of hormone
replacement therapy. Somewhat surprisingly, relatively little is
known about the mechanisms of this form of BTB, although there
are some simularities to BTB associated with progestogen-only
contraception (Thomas et al., 2000).

Conclusion
Abnormal uterine bleeding is a very common gynaecological
problem, with varied presentations and multiple causes. Over the
past 1015 years there has been a major escalation in the scientic
effort aimed at elucidating the underlying mechanisms. It is now
clear that these mechanisms are complex and involve a number of
different molecular systems. This review has attempted to pull
together the evidence from different disciplines to provide a
picture of the way in which these systems interact to cause
different symptoms.

References
Adelantado, J.M., Rees, M.C.P., Lopez Bernal, A. et al. (1988) Increased
uterine prostaglandin receptors in menorrhagic women. Br. J. Obstet.
Gynaecol., 95, 162165.
Akerlund, M. Bengtsson, L.P. and Carter, A.M. (1975) A technique for
monitoring endometrial or decidual blood ow with an intrauterine
thermistor probe. Acta Obstet. Gynecol. Scand., 54, 469477.
Andersson, K. and Rybo, G. (1990) Levonorgestrel-releasing intrauterine
device in the treatment of menorrhagia. Br. J. Obstet. Gynaecol., 97, 690
694.
Andrade, A.T.L. and Pizarro-Orchard, E. (1987) Quantitative studies on
menstrual blood loss in IUD users. Contraception, 33, 111119.
Aplin, J.D., Charlton, A.K. and Ayad, S. (1988) An immunohistochemical
study of human endometrial extracellular matrix during the menstrual
cycle and the rst trimester of pregnancy. Cell Tiss. Res., 253, 231240.
Arici, A., Seli, E., Semturk, L.M. et al. (1998) Interleukin-8 in human
endometrium. J. Clin. Endocrinol. Metab., 83, 17831787.
Baird, D.T., Cameron, S.T., Critchley, H.O.D. et al. (1996). Prostaglandins
and menstruation. Eur. J. Obstet. Gynecol. Reprod. Biol. 70, 1517.
Ballinger, C.V., Browning, N.C. and Smith, A.H.W. (1987). Hormonal proles
and psychological symptoms in perimenopausal women. Maturitas, 9,
235251.
Beazley, J.M. (1972) Dysfunctional uterine haemorrhage. Br. J. Hosp. Med., 7,
573578.
Beilby, J.O.W., Farrer-Brown, G. and Tarbit, M.H. (1971) The
microvasculature of common uterine abnormalities, other than broids,
J. Obstet. Gynaecol. Br. Commonw., 78, 361368.
Belsey, E.M. and Task Force on Long-acting Systemic Agents for Fertility
Regulation (1988) The association between vaginal bleeding patterns and
reasons for discontinuation of contraceptive use. Contraception, 38, 207
225.
Bonnar, J., Sheppard, B.L. and Dockeray, C.L. (1983) The haemostatic system
and dysfunctional uterine bleeding. Res. Clin. Forums, 5, 2736.
Brown, J.B., Kellar, R.J. and Matthew, G.D. (1959) Urinary oestrogen
excretion in certain gynaecological disorders. J. Obstet. Gynaecol. Br.
Emp., 66, 177211.
Bulmer, J.N., Johnson, P.M. and Bulmer, D. (1987) Leucocyte populations in
human decidua and endometrium. In Gill, T.J. III, Wegmann, T.J. (eds)
Immunoregulation and Fetal Survival. Oxford University Press, New
York, pp. 111134.
Cameron, I.T. (1989) Dysfunctional uterine bleeding. In Drife, J.O. (ed.)
Dysfunctional uterine bleeding and menorrhagia. Bailliere's Clin. Obstet.
Gynaecol., 3, 315328.
Cameron, I.T., Davenport, A.P., van Papendorp, C. et al. (1992) Endothelinlike immunoreactivity in human endometrium. J. Reprod. Fertil., 95, 623
628.
Casslen, B., Andersson, A. and Nilsson, I.M. (1986) Hormonal regulation of
the release of plasminogen activators and of a specic activator inhibitor
from endometrial tissues in culture. Proc. Soc. Exp. Biol. Med., 182, 419
424.
Charnock-Jones, D.S., Macpherson, A.M., Archer, D.F. et al. (2000) The
effect of progestins on vascular endothelial growth factor, oestrogen
receptor and progesterone receptor immunoreactivity and endothelial
density in human endometrium. Hum. Reprod., 15 (suppl. 3), 8595.
Chimbira, T.H., Anderson, A.B.M. and Turnbull, A.C. (1980) Relationship
between measured menstrual blood loss and patients subjective
assessment of loss, duration of bleeding, number of sanitary towels
used, uterine weight and endometrial surface area. Br. J. Obstet.
Gynaecol., 87, 603609.
Christiaens, G.C.M.L., Sixma, J.J. and Haspels, A.A. (1982) Hemostasis in
menstrual endometrium: a review. Am. J. Reprod. Immunol., 5, 7883.
Chwalisz, K. and Gareld, R.E. (2000) Role of nitric oxide in implantation and
menstruation. Hum. Reprod., 15 (suppl. 3), 96111.
Claessens, E.A. and Cowell, C.A. (1981) Acute adolescent menorrhagia. Am.
J. Obstet. Gynecol., 139, 277282.
Clark, D.A. (1993) Cytokines, decidua and pregnancy. Oxford Rev. Reprod.
Biol., 15, 83111.
Clark, D.A., Wang, S., Rogers P.A.W. et al. (1996) Endometrial
lymphomyeloid cells in abnormal uterine bleeding due to levonorgestrel
(Norplant). Hum. Reprod., 11, 14381444.
Cole, S.K., Billewicz, W.Z. and Thomson, A.M. (1971) Sources of variation in
menstrual blood loss. J. Obstet. Gynaecol. Br. Commonw., 78, 933939.
Cowan, B.D. (1992) Dysfunctional uterine bleeding: clues to efcacious

65

M.Livingstone and I.S.Fraser

approaches. In Alexander, N.J. and d'Arcangues, C. (eds) Steroid
Hormones and Uterine Bleeding. AAAS Press, Washington, pp. 914.
Critchley, H.O.D., Abberton, K.M., Taylor, N.H. et al. (1994). Endometrial
sex steroid receptor expression in women with menorrhagia. Br. J. Obstet.
Gynaecol., 101, 428434.
De Duve, C. and Wattiaux, R., (1966) Functions of lysosomes. Am. Rev.
Physiol., 28, 435492.
Downie, J., Poyser, N.L. and Wunderlich, M. (1974) Levels of prostaglandins
in human endometrium during the normal menstrual cycle. J. Physiol.,
236, 465472.
Einer-Jensen, N. (1973) Decreased endometrial blood ow and plasma
progesterone level after instillation of 10mg of prostaglandin F2a into the
lumen of the uteri of Rhesus monkeys. Prostaglandins, 4, 517522.
Eldred, J.M. and Thomas, E.J. (1994) Pituitary and ovarian hormone levels in
unexplained menorrhagia. Obstet. Gynecol., 84, 775778.
Ferenczy, A. (1976a) Studies on the cytodynamics of human endometrial
regeneration I. Scanning electron microscopy. Am. J. Obstet. Gynecol.,
124, 6474.
Ferenczy, A. (1976b) Studies on the cytodynamics of human endometrial
regeneration II. Transmission electron microscopy and histochemistry.
Am. J. Obstet. Gynecol., 124, 582595.
Findlay, J.K. (1986) Angiogenesis in reproductive tissues. J. Endocrinol., 111,
357366.
Finn, C.A. (1986) Implantation, menstruation and inammation. Biol. Rev.,
61, 313328.
Fraser, I.S. (1989) Treatment of menorrhagia. In Drife, J.O. (ed.)
Dysfunctional Uterine Bleeding. Bailliere's Clin. Obstet. Gynaecol., 3,
391402.
Fraser, I.S. and Diczfalusy, E. (1980) A perspective of steroidal contraception
and abnormal uterine bleeding: what are the prospects for improvement?
In Diczfalusy, E., Fraser, I.S. and Webb, F.T.G. (eds) Endometrial
Bleeding and Steroidal Contraception. Pitman Press, Bath, pp. 384413.
Fraser, I.S. and Petrucco, O.M. (1996) Management of intermenstrual and
postcoital bleeding, and an appreciation of the issues arising out of the
recent case of O'Shea v Sullivan and Macquarie Pathology. Aust. NZ J.
Obstet. Gynaecol., 36, 6773.
Fraser, I.S. and Sungurtekin, U. (2000) Dening menstrual disturbances. In
Maclean, A. and O'Brien, P.M.S. (eds) Study Group on Menstrual
Disorders. Royal College of Obstetricians and Gynaecologists, pp. 141
152.
Fraser, I.S., McCarron, G. and Markham, R. (1984) A preliminary study of
factors inuencing perception of menstrual blood loss volume. Am. J.
Obstet. Gynecol., 149, 788793.
Fraser, I.S., Baird, D.T., Michie, E.A. et al. (1973) Pituitary gonadotropins and
ovarian function in adolescent dysfunctional uterine bleeding. J. Clin.
Endocrinol. Metab., 37, 407414.
Fraser, I.S., Pearse, C., Shearman, R.P. et al. (1981) Efcacy of mefenamic
acid in patients with a complaint of menorrhagia. Obstet. Gynecol., 58,
54351
Fraser, I.S., McCarron, G., Markham, R. et al. (1985) Blood and uid content
of menstrual discharge. Obstet. Gynecol., 65, 194198.
Fraser, I.S., McCarron, G., Hutton, B. et al. (1987) Endometrial blood ow
measured by xenon-133 clearance in women with normal menstrual
cycles and dysfunctional uterine bleeding. Am. J. Obstet. Gynecol., 156,
158166.
Fraser, I.S., Hickey, M. and Song, J.Y. (1996) A comparison of mechanisms
underlying disturbances of bleeding caused by spontaneous dysfunctional
uterine bleeding or hormonal contraception. Hum. Reprod., 11 (suppl. 2),
165178.
Gleeson, N., Devitt, M., Sheppard, B.L. et al. (1993) Endometrial brinolytic
enzymes in women with normal menstruation and dysfunctional uterine
bleeding. Br. J. Obstet Gynaecol., 100, 768771.
Greenberg, M. (1983) The meaning of menorrhagia: an investigation into the
association between the complaint of menorrhagia and depression. J.
Psychosom. Res., 27, 209214.
Hallberg, L. and Nilsson, L. (1964) Determination of menstrual blood loss.
Scand. J. Clin. Lab. Invest., 16, 244
Hallberg, L., Hogdahl, A., Nilsson, L. et al. (1966) Menstrual blood lossa
population study. Acta Obstet. Gynecol. Scand., 45, 320351.
Hamou, J. (1985) Hysteroscopy and Microcolpohysteroscopy. Appleton and
Lange, Norwalk, Connecticut.
Hampton, A.L. and Salmonsen, L.A. (1994) Expression of messenger
ribonucleic acid encoding matrix metalloproteinases and their tissue
inhibitors is related to menstruation. J. Endocrinol., 141, R13.

66

Haynes, P.J., Anderson, A.B.M. and Turnbull, A.C. (1979) Patterns of

menstrual blood loss in menorrhagia. Res. Clin. Forums, 1, 7378.
Henzl, M.R., Smith, R.E., Boost, G. et al. (1972) Lysosomal concept of
menstrual bleeding in humans. J. Clin. Endocrinol. Metab., 34, 860875.
Hickey, M. and Fraser, I.S. (2000) A functional model for progestogen-only
breakthrough bleeding. Hum. Reprod., 15 (suppl. 3), 16.
Hickey, M., Fraser, I.S., Dwarte, D. et al. (1996) Endometrial vasculature in
Norplant users: preliminary results from a hysteroscopic study. Hum
Reprod., 11, (suppl. 2), 3544.
Hickey, M., Dwarte, D. and Fraser, I.S. (1998) Precise measurements of
intrauterine vascular structures at hysteroscopy in menorrhagia and during
Norplant use. Hum. Reprod., 13, 31903196.
Hickey, M., Simbar, M., Markham, R. et al. (1999) Changes in endothelial cell
basement membrane in Norplant users. Hum. Reprod., 14, 716721.
Hickey, M., Dwarte, D. and Fraser, I.S. (2000a) Supercial endometrial
vascular fragility in Norplant users and in women with ovulatory
dysfunctional uterine bleeding. Hum. Reprod., 15, 15091514.
Hickey, M., Carati, C., Manconi, F. et al. (2000b) The measurement of
endometrial perfusion in Norplant users. Hum. Reprod., 15, 10861091.
Higham, J.M., O'Brien, P.M.S. and Shaw, R.W. (1990) Assessment of
menstrual blood loss using a pictorial chart. Br. J. Obstet. Gynaecol., 97,
734739.
Hourihan, H., Sheppard, B.L. and Bonnar, J. (1989) The morphologic
characteristics of menstrual haemostasis in patients with unexplained
menorrhagia. Int. J. Gynecol. Pathol., 8, 221229.
Hurskainen, R., Teperi, J., Turpeinen, U. et al. (1998) Combined laboratory
and diary method for objective assessment of menstrual blood loss. Acta
Obstet. Gynecol. Scand., 77, 201204.
Jeziorska, M. Nagase, H., Salamonsen, L.A. et al. (1996) Immunolocalisation
of the matrix metalloproteinases, gelatinase B and stromelysin-1 in human
endometrium throughout the menstrual cycle. J. Reprod. Fertil., 107, 43
51.
Jones, A. and Harris, A.L. (1998) New developments in angiogenesis: a major
mechanism for tumor growth and target for therapy. Cancer J. Sci. Am., 4,
209217.
Kamat, B.R. and Isaacson, P.G. (1987) Immunocytochemical distribution of
leucocyte subpopulations in human endometrium. Am. J. Pathol., 127,
6673.
Kooy, J., Taylor, N.H., Healy, D.L. et al. (1996). Endothelial cell proliferation
in the endometrium of women with menorrhagia and in women following
endometrial ablation. Hum. Reprod., 11, 10671072.
Kothapalli, R., Buyuksal, I., Wu, S.Q. et al. (2000) Detection of ebaf, a novel
human gene of the transforming growth factor-beta superfamily. J. Clin.
Invest., 99, 23422350.
Lathbury, L.J. and Salamonsen, L.A. (1999) Identication of a role for
neutrophils in the process of menstruation. Mol. Hum. Reprod., 6, 899
906.
Lockwood, C.J., Nemerson, Y., Krikun, G. et al. (1993) Steroid-modulated
stromal cell tissue factor expression: a model for the regulation of
endometrial hemostasis and menstruation. J. Clin. Endocrinol. Metab., 77,
10141019.
Lockwood, C.J., Krikun, G., Hausknecht, V.A. et al. (1998) Matrix
metalloproteinase and matrix metalloproteinase inhibitor expression in
endometrial stromal cells during progestin-initiated decidualization and
menstruation-related progestin withdrawal. Endocrinology, 139, 4607
4613.
Lockwood, C.J., Runic, R., Wan, L. et al. (2000) The role of tissue factor in
regulating endometrial haemostasis: implications for progestin-only
contraception. Hum. Reprod., 15 (suppl. 3), 144151.
Maqueo, M. (1980) Vascular and perivascular changes in the endometrium of
women using steroidal contraceptives. In Diczfalusy, E., Fraser, I.S. and
Webb, F.T.G. (eds) Enmdometrial Bleeding and Steroidal Contraception,
Pitman Press, Bath, pp. 138152.
Marbaix, E., Kokorine, I., Moulin, P. et al. (1996) Menstrual breakdown of
human endometrium can be mimicked in vitro and is selectively and
reversibly blocked by inhibitors of matrix metalloproteinases. Proc. Natl
Acad. Sci. USA, 93, 91209125.
Marbaix, E., Vekemans, M., Galant, C., et al. (2000) Circulating sex hormones
and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of
bleeding episodes in levonorgestrel-implant users. Hum. Reprod., 15
(suppl. 3), 120134.
Marsh, M.M., Butt, A.R., Riley, S.C. et al. (1995) Immunolocalisation of
endothelin and neutral endopeptidase in the endometrium ofusers of
subdermally implanted levonorgestrel (Norplant). Hum. Reprod., 10,
25842589.

Marsh, M.M., Findlay, J.K. and Salamonsen, L.A. (1996) Endothelin and
menstruation. Hum. Reprod., 11, 8389.
Matsumoto, S., Nogani,Y. and Ohkuri, S. (1962) Statistical studies on
menstruation: A criticism on the denition of normal menstruation.
Gunma J. Med. Sci., 11, 294318.
Matsuzaki, S., Fukaya,
Salamonsen, xBT
/F2N-1.124 lN2e